gex-2 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
How to validate GEX-2 antibody specificity in embryonic cell migration studies?
Methodology:
-
Perform RNA interference (RNAi) knockdown of gex-2 in C. elegans embryos and compare immunostaining patterns to wild-type controls .
-
Use co-immunoprecipitation (Co-IP) with GEX-3 to confirm interaction, as GEX-2 requires GEX-3 for stable complex formation at cell boundaries .
-
Include negative controls (e.g., gex-2(RNAi) embryos) to ensure antibody signal loss in knockout conditions.
Validation Table:
| Assay Type | Expected Outcome (Wild-Type) | Expected Outcome (Knockout) |
|---|---|---|
| Immunostaining | Enriched basolateral signal at cell boundaries | Signal absence at boundaries |
| Western Blot | ~140 kDa band in total protein extract | No detectable band |
What experimental designs optimize GEX-2 localization studies in morphogenesis?
Best Practices:
-
Use confocal microscopy with ≤0.5 μm Z-stacks to resolve basolateral vs. apical localization (AJM-1 serves as apical marker) .
-
Combine with GFP-tagged rescue constructs (e.g., gex-3::gfp) to verify antibody specificity in genetic backgrounds.
-
Synchronize embryo collection to stage-specific timepoints (e.g., 100-cell stage) for dynamic localization analysis.
How to resolve conflicting data on GEX-2’s role in Rac signaling pathways?
Analysis Framework:
-
Contextualize model systems: C. elegans GEX-2 lacks direct Rac-binding domains observed in mammalian homologs .
-
Functional assays: Compare cell migration phenotypes in ced-10(n1993) (Rac mutant) vs. gex-2(RNAi) embryos.
-
Biochemical profiling: Perform pulldown assays with constitutively active Rac GTPase to test indirect interactions.
Key Finding:
GEX-2/GEX-3 complexes in C. elegans regulate cell shape independently of direct Rac binding, suggesting evolutionary divergence from vertebrate pathways .
What methods address cross-reactivity in GEX-2 antibody applications for non-model organisms?
Stepwise Approach:
-
Epitope mapping: Align target species’ GEX-2 sequence with C. elegans immunogen (e.g., residues 800-950 critical for antibody binding ).
-
Tissue-specific validation: Test antibody in organoids or primary cell cultures with CRISPR-Cas9 knockout controls.
-
Multiplex imaging: Pair with conserved markers (e.g., β-catenin) to confirm subcellular localization patterns.
How to troubleshoot inconsistent GEX-2 immunostaining in hypodermal cells?
Technical Solutions:
| Issue | Root Cause | Mitigation |
|---|---|---|
| Patchy signal | Transient protein turnover during enclosure | Fix embryos <30 min post-dissection |
| Non-specific background | Autofluorescence in late-stage embryos | Use near-infrared secondary antibodies |
| Signal loss | Over-permeabilization | Optimize Triton X-100 concentration (0.1–0.3%) |
Distinguishing artifact vs. biological signal in GEX-2 co-localization studies
-
Control experiments: Compare antibody staining with transgenic gex-2::mCherry lines.
-
Quantitative thresholds: Define co-localization as Pearson’s correlation coefficient >0.7 in ≥3 biological replicates.
-
Dynamic analysis: Perform time-lapse imaging to track GEX-2 redistribution during cell shape changes.
Critical Insight:
GEX-2 exhibits polarized enrichment at leading edges of migrating hypodermal cells, which may be misinterpreted as "diffuse" signal in static images .
Integrating GEX-2 antibody data with single-cell transcriptomics (e.g., 10x Genomics GEX)
Workflow:
-
Spatial correlation: Map scRNA-seq clusters (e.g., intestinal plasma cells ) to antibody-based protein localization.
-
Multimodal validation: Use CODEX or MERFISH to overlay GEX-2 protein distribution with gex-2 mRNA hotspots.
Limitation: Antibody-based detection may not align with transcriptional activity in terminally differentiated cells due to post-transcriptional regulation.
